Blue March Campaign 2024

Facts on CRC

Colorectal cancer (CRC) is the third most common cancer in the world,1 with 1 in 4 people diagnosed when the disease has already metastasised (stage IV)2
  • Approximately 1.9 million cases are diagnosed annually, of which approximately 520,000 are diagnosed in Europe.1
  • Globally, the incidense of CRC is expected to rise to more than 3 million cases per year by 2040.3
  • It mainly affects people over 50,4 but there is a rising incidence in younger people.3
  • Colorectal cancer can have better outcomes if diagnosed early.3

Preventing CRC

There are simple ways to lower your risk of getting colorectal cancer5 that you can incorporate into your daily routine
  • A daily intake of fibre from fruits, vegetables, legumes and whole grains can help lower your risk of getting colorectal cancer.5
  • Regular physical activity can help lower your risk of getting colorectal cancer.5 Put on your running shoes, ski boots or ballet shoes and get active.
  • Stress can lead to certain behaviours such as smoking, unbalanced diet behaviours, and drinking too much, which have been shown to increase the risk of cancers. Relaxation and meditation methods could help you reduce your stress levels and in turn reduce these behaviours.6

Symptoms & Screening of CRC

It may not always be easy to spot the signs or symptoms of CRC7 - but it is important to know when to call your doctor
  • Early diagnosis of colorectal cancer is vital. While some symptoms may alert you, early detection through an effective and regular screening test is the most reliable prevention method.8
  • Symptoms may include, but are not limited to:
    • A change in bowel habits7
    • Diarrhoea, constipation or feeling that the bowel does not empty completely7
    • Blood in stool7
    • Discomfort in the abdomen7
    • Weight loss with no known explanation7
    • Constant tiredness or fatigue7
  • If you are concerned, speak to your doctor to learn more about symptoms and screening programmes available.

Biomarker Testing

Every CRC tumour has unique characteristics9 and biomarker testing at mCRC diagnosis will help your medical team to personalise your treatment journey9
  • Biomarker testing is critical at mCRC diagnosis to help each medical team determine the appropriate treatment pathway for each patient.9
  • Biomarker testing supports treatment decisions for patients with mCRC, because a large percentage of mCRCs harbour specific genetic modifications that define response (or lack of response) to therapy.10-12

Pierre Fabre's CRC Commitment

Pierre Fabre is driven by its commitment to improving the lives of people with cancers where there are currently limited treatment options.

Pierre Fabre is pursuing the development of cancer therapies in areas with high medical need, with a goal of advancing care for individuals with challenging cancers.

Patient's needs are the root of Pierre Fabre's research and clinical development programmes, and our R&D strategy has a heavy emphasis on innovative biomarker-driven treatments.


1 The Global Cancer Observatory, 2020. International Agency for Research on Cancer, World Health Organization. Available at: Accessed January 2024.
2 Van Cutsem E, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1-iii9.
3 Gunter MJ, et al. Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer. Ann Oncol. 2019;doi: 10.1093/annonc/mdz044.
4 American Cancer Society. Colorectal Cancer Facts and Figures 2020-2022. Available at: Accessed January 2024.
5 Kerr J, et al. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017; 18(8):e457-71. doi: 10.1016/S1470-2045(17)30411-4.
6 National Cancer Institute. Psychological Stress and Cancer. Available at: Accessed January 2024.
7 Cancer.Net. Colorectal Cancer: Symptoms and Signs. Available at: Accessed January 2024.
8 American Cancer Society. Colorectal Cancer Prevention. Available at: Colorectal Cancer Prevention | How to Prevent Colorectal Cancer. Accessed January 2024.
9 Van Cutsem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422.
10 Yokota T, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104:856-62.
11 Loupakis F, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101:715-21.
12 Kafatos G, et al. RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomark Med. 2017;11(9):751-760
Pierre Fabre använder cookies och andra spårningsfunktioner för att optimera webbplatsens prestanda och funktionalitet, mäta målgruppen och anpassa innehållet (annonseringen) efter dina intresseområden. Mer information om hanteringen av dina personuppgifter och dina rättigheter finns i vår sekretesspolicy. Om du vill ställa in eller inaktivera cookies klickar du på Cookie-inställningar.
Är du hälso- och sjukvårdspersonal?
Denna site är avsedd för hälso- och sjukvårdspersonal i Sverige, klicka ja nedan så kommer du in på webbplatsen. Klickar du nej kommer du till

Du öppnar nu en extern webbplats

Pierre-Fabre ansvarar inte för innehållet på andras hemsidor. Klicka på "Öppna länk" om du vill fortsätta.
Öppna länk